Formycon AG (FRA:FYB)
22.80
-0.05 (-0.22%)
Last updated: Dec 3, 2025, 1:46 PM CET
Formycon AG Revenue
Formycon AG had revenue of 9.00M EUR in the half year ending June 30, 2025, a decrease of -79.45%. This brings the company's revenue in the last twelve months to 48.07M, down -17.19% year-over-year. In the year 2024, Formycon AG had annual revenue of 69.67M, down -10.32%.
Revenue (ttm)
48.07M
Revenue Growth
-17.19%
P/S Ratio
9.17
Revenue / Employee
192.30K
Employees
250
Market Cap
440.73M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 69.67M | -8.02M | -10.32% |
| Dec 31, 2023 | 77.70M | 35.20M | 82.83% |
| Dec 31, 2022 | 42.50M | 5.88M | 16.07% |
| Dec 31, 2021 | 36.61M | 2.32M | 6.76% |
| Dec 31, 2020 | 34.30M | 1.14M | 3.43% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| SAP SE | 36.49B |
| Siemens Aktiengesellschaft | 78.91B |
| Allianz SE | 105.02B |
| Deutsche Telekom AG | 121.02B |
| Siemens Energy AG | 39.08B |
| Rheinmetall AG | 11.00B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.10B |
| Deutsche Bank Aktiengesellschaft | 29.86B |
Formycon AG News
- 2 days ago - Formycon, MS Pharma Sign Commercialization Partnership For Keytruda Biosimilar - Nasdaq
- 2 days ago - EQS-News: Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda biosimilar candidate FYB206 for the MENA Region - Wallstreet:Online
- 12 days ago - EQS-News: NTC becomes commercialization partner for Formycon’s Eylea biosimilar FYB203/Baiama in Italy - Wallstreet:Online
- 15 days ago - Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy • news - Onvista
- 16 days ago - EQS-News: Ranibizumab Biosimilar Epruvy launched in Germany - Wallstreet:Online
- 19 days ago - EQS-News: Formycon achieves key development milestone with FYB208: Biosimilar candidate for Dupixent (dupilumab) adds another growth driver to the biosimilar portfolio - Wallstreet:Online
- 20 days ago - Formycon AG 2025 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 21 days ago - Positioning Barbados as the Caribbean's Life Sciences Hub - Benzinga